Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.

The Journal of antimicrobial chemotherapy - 1 Jan 2014

Leeds Jennifer A, Sachdeva Meena, Mullin Steve, Barnes S Whitney, Ruzin Alexey

Abstract excerpt

OBJECTIVES: Current treatments for Clostridium difficile infection include vancomycin, metronidazole and fidaxomicin. LFF571 is an experimental agent undergoing evaluation in humans for the treatment of moderate C. difficile infection. Reduced susceptibility of C. difficile to fidaxomicin or LFF571 in vitro can be mediated by single point mutations in genes encoding the targets, whereas the mechanism(s) mediating...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoglycosides
Share to Cell Wall

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clostridioides difficile

Share to DNA-Directed RNA Polymerases

Share to Genome, Bacterial

Share to Serial Passage

Share to Thiazoles

Share to Vancomycin

Source

Identifiers

PMID: 23887866
DOI: 10.1093/jac/dkt302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.PMID 23887866Read ↗

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read ↗

Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoBSemantic proximity Read ↗

<i>In vivo</i> efficacy of fidaxomicin against <i>rpoB</i> mutant <i>Clostridioides difficile</i> infectionSemantic proximity Read ↗

Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.Semantic proximity Read ↗

Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.Semantic proximity Read ↗

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficileSemantic proximity Read ↗

Identification of pathways to high-level vancomycin resistance in Clostridioides difficile that incur high fitness costs in key pathogenicity traits.Semantic proximity Read ↗

Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate.Semantic proximity Read ↗

Multiple evolutionary pathways lead to vancomycin resistance in <i>Clostridioides difficile</i>Semantic proximity Read ↗

Constitutive expression of the cryptic vanGCd operon promotes vancomycin resistance in Clostridioides difficile clinical isolatesSemantic proximity Read ↗

Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.Semantic proximity Read ↗

Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.